OFIRMEV (acetaminophen IV)

Background: 1
•    Cadence Pharmaceuticals’ proprietary intravenous formulation of acetaminophen.
•    Same product was marketed in Europe since 2002 as Perfalgan (also under the name Acetavance) by Bristol-Meyers Squibb.
•    Cadence acquired the exclusive rights to OFIRMEV in the US and Canada in 2006.
•    NDA was filed in 2009

Paracetamol (Perfalgan) solution for infusion 2
1.    Therapeutic indication:  Short-term treatment of moderate pain, especially following surgery, and for short-term treatment of fever, when administration by intravenous route is clinically justified by an urgent need to treat pain or hyperthermia and/or when other routes of administration are not possible
2.    Dosage:  Adults: 1gm Q4H, max 4gm per day
Children: 15mg/kg up Q4H to 4 times a day, max dose: 60mg/kg/day
(3g/day children >=33kg or 2g/day for children with weight between 10 & 33kg)
Severe renal insufficiency (CrCL =30ml/min): Q6H
Hepatocellular insufficiency, chronic alcoholism, chronic malnutrition, dehydration: maximum 3g/day.
3.    Method of administration: IV infusion over 15 minutes.
Can be diluted with NS or D5W, but must be infused within 1 hour including the infusion time.
4.    Pharmacological properties:
    Pain relief: onset: 5-10 minutes after the start of infusion, peak is 1 hour, duration: 4-6 hours.
    Fever: onset: within 30 minutes, duration: 6 hours.
5.    Contraindications, DDI, S/E: similar to Tylenol.

Clinical Trial:
•    2 pivotal clinical trials for the treatment of acute pain in patients following orthopedic surgery
•    1 pivotal clinical trial for the treatment of fever
•    9 placebo-controlled clinical trials
•    4 active-controlled clinical trials
•    7 other safety or pharmacokinetic trials

1.  A Phase III, Multi-Center, Randomized, Double-blind, Placebo-Controlled 24 Hour Study of the Efficacy and Safety of Intravenous Acetaminophen in Abdominal Laparoscopic Surgery3
Trial number: NCT0064486
Duration: Nov 2007 – Nov 2008
Inclusion criteria: patients with pain intensity (PI) at least moderate on a 4-point categorical scale and >=40 and <=70mm on a 100mm visual analog scale.
Primary efficacy endpoint: weighted sum of PI differences over 24h comparing IV APAP 1g vs. the combined placebo group.

IV APAP (1g)     IV APAP (650mg)    Placebo
N (Total = 244)    92    42    110
Pain Intensity    Significantly reduced PI (p=0.0068)    Significantly reduced PI (p=0.0183)
Satisfactory rating to the treatment for their pain    More satisfactory than placebo

Time to meaningful pain relief     Shorter than placebo (p=0.0029)
Tolerability    Similar adverse event profile (including hepatic event) between IV APAP regimens and placebo

2.    A Randomized, Four-period, Crossover Pharmacokinetic trial 4
Trial number: NCT00564629
Subjects: 32 adult males
Treatment: IV Acetavance vs. oral acetaminophen
Result: IV Acetavance had comparable pharmacokinetics, pharmacodynamics and a similar side effect profile to oral acetaminophen

3.    A Randomized, Double-blind, Placebo Controlled, Single Dose, Phase III Trial 4
Trial number: NCT00493311
Subjects: healthy volunteers
Treatment: IV paracetamol or placebo following endotoxin-induced fever.
Result: fever significantly reduced over 6 hours in IV paracetamol group

Trouble in Getting Approval by FDA: 1
•    Deficiencies were observed during the FDA’s facility inspection of Cadence’s third party manufacturer.
•    No safety or efficacy issues were cited
•    No additional studies need to be conducted.
•    Cadence plans to request a meeting with the FDA to ensure the deficiencies have been addressed to meet the requirement for NDA approval.

Clinical Advantage of IV APAP:
•    Patients with N/V that can not tolerate PO formulation.
•    NPO patients
•    Neutropenic patients who cannot use suppository formulation.
•    Better side effects profile compared to IV NSAID or opioid.
•    An excellent anti-pyretic or mild analgesic agent for oncology patients.

Detox FootPatchPad

Posted on มกราคม 24, 2013, in บทความ. Bookmark the permalink. ใส่ความเห็น.

ใส่ความเห็น

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / เปลี่ยนแปลง )

Twitter picture

You are commenting using your Twitter account. Log Out / เปลี่ยนแปลง )

Facebook photo

You are commenting using your Facebook account. Log Out / เปลี่ยนแปลง )

Google+ photo

You are commenting using your Google+ account. Log Out / เปลี่ยนแปลง )

Connecting to %s

%d bloggers like this: